Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Gastrointestinal Cancers
•
Medical Oncology
What neoadjuvant treatment strategy would you use for an unresectable intrahepatic cholangiocarcinoma with dMMR with the goal of downstaging to achieve surgical resectability?
Patient with ECOG 0-1
Related Questions
How will the PROSPECT trial presented at ASCO 2023 change your current management of early rectal cancer?
What is your preferred chemotherapy regimen in concurrent chemo-radiation in esophageal adenocarcinoma (either pre-op or definitive)?
How do you manage a recurrence of colon cancer within 3-4 months of completion of adjuvant FOLFOX?
How would you treat an MSI-H metastatic cholangiocarcinoma found on liquid biopsy?
In what situations would you treat a rectal mass as cancer despite negative biopsies?
In patients with resected PDAC treated with adjuvant FOLFIRINOX who recur from 1-3 years post completion of adjuvant therapy, do you consider retreatment with FOLFIRINOX or gemcitabine/nab-paclitaxel in the absence of a clinical trial?
Would you recommend off-label use of chemoimmunotherapy for metastatic anal squamous cell cancer?
How do you employ focal therapies in localized hepatocellular carcinoma?
How do you approach a low grade intra-cholecystic papillary neoplasm of the gallbladder without invasive component and reported surgical pathology with negative margins ?
How, if at all, are you employing ctDNA in the management of patients with colon cancer?